123 related articles for article (PubMed ID: 33550637)
1. Novel EGFL7-FOSB fusion in pseudomyogenic haemangioendothelioma with widely metastatic disease.
Hakar MH; White K; Hansford BG; Swensen J; Davis JL
Histopathology; 2021 Nov; 79(5):888-891. PubMed ID: 33550637
[No Abstract] [Full Text] [Related]
2. Diverse clinical presentations of pseudomyogenic hemangioendothelioma associated with EGFL7::FOSB fusion: a second case.
Li B; Zhang C; Zhao L; Chen N; Hu Y; Li Z; Kang S; Blake A; Xiao S
Histopathology; 2024 Mar; 84(4):708-712. PubMed ID: 38012540
[No Abstract] [Full Text] [Related]
3. Primary pseudomyogenic haemangioendothelioma of the testis with a novel POTEI::FOSB gene fusion.
Gersmann AK; Haller F; Behnert N; Richter A; Stöhr R; Hartmann A; Ströbel P; Bremmer F
Histopathology; 2022 Sep; 81(3):411-414. PubMed ID: 35582841
[No Abstract] [Full Text] [Related]
4. Fusion of the Genes
Panagopoulos I; Lobmaier I; Gorunova L; Heim S
Cancer Genomics Proteomics; 2019; 16(4):293-298. PubMed ID: 31243110
[TBL] [Abstract][Full Text] [Related]
5. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma.
Walther C; Tayebwa J; Lilljebjörn H; Magnusson L; Nilsson J; von Steyern FV; Øra I; Domanski HA; Fioretos T; Nord KH; Fletcher CD; Mertens F
J Pathol; 2014 Apr; 232(5):534-40. PubMed ID: 24374978
[TBL] [Abstract][Full Text] [Related]
6. A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone.
Bridge JA; Sumegi J; Royce T; Baker M; Linos K
Genes Chromosomes Cancer; 2021 Jan; 60(1):38-42. PubMed ID: 32749039
[TBL] [Abstract][Full Text] [Related]
7. Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.
Agaram NP; Zhang L; Cotzia P; Antonescu CR
Am J Surg Pathol; 2018 Dec; 42(12):1653-1661. PubMed ID: 30256258
[TBL] [Abstract][Full Text] [Related]
8. Penile pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma with a novel pattern of SERPINE1-FOSB fusion detected by RT-PCR--report of a case.
Ide YH; Tsukamoto Y; Ito T; Watanabe T; Nakagawa N; Haneda T; Nagai M; Yamanishi K; Hirota S
Pathol Res Pract; 2015 May; 211(5):415-20. PubMed ID: 25749627
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous pseudomyogenic (epithelioid sarcoma-like) haemangioendothelioma FOSB immunohistochemistry demonstrating the SERPINE1-FOSB fusion gene.
Alegría-Landa V; Santonja C; Jo-Velasco M; Kutzner H; Requena L
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e550-e552. PubMed ID: 28622428
[No Abstract] [Full Text] [Related]
10. A novel SERPINE1-FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K-AKT-mTOR signaling pathway and responsiveness to sirolimus.
Ren J; Wang X; Zhou Y; Yue X; Chen S; Ding X; Zeng S; Jiang X; Liu X; Guo Q
J Dermatol; 2021 Dec; 48(12):1900-1906. PubMed ID: 34580903
[TBL] [Abstract][Full Text] [Related]
11. Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma.
Ozeki M; Nozawa A; Kanda K; Hori T; Nagano A; Shimada A; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):e328-e331. PubMed ID: 28121744
[TBL] [Abstract][Full Text] [Related]
12. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma.
Hung YP; Fletcher CD; Hornick JL
Am J Surg Pathol; 2017 May; 41(5):596-606. PubMed ID: 28009608
[TBL] [Abstract][Full Text] [Related]
13. ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features.
Antonescu CR; Chen HW; Zhang L; Sung YS; Panicek D; Agaram NP; Dickson BC; Krausz T; Fletcher CD
Genes Chromosomes Cancer; 2014 Nov; 53(11):951-9. PubMed ID: 25043949
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics.
Sugita S; Hirano H; Kikuchi N; Kubo T; Asanuma H; Aoyama T; Emori M; Hasegawa T
Diagn Pathol; 2016 Aug; 11(1):75. PubMed ID: 27515856
[TBL] [Abstract][Full Text] [Related]
15. New kids on the block:
Cordier F; Creytens D
J Clin Pathol; 2023 Nov; 76(11):721-726. PubMed ID: 37553246
[No Abstract] [Full Text] [Related]
16. Role of EGFL7 in human cancers: A review.
de Oliveira C; Gonçalves PG; Bidinotto LT
J Cell Physiol; 2023 Aug; 238(8):1756-1767. PubMed ID: 37490307
[TBL] [Abstract][Full Text] [Related]
17. Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.
van IJzendoorn DGP; Sleijfer S; Gelderblom H; Eskens FALM; van Leenders GJLH; Szuhai K; Bovée JVMG
Clin Cancer Res; 2018 Jun; 24(11):2678-2687. PubMed ID: 29511030
[No Abstract] [Full Text] [Related]
18. Molecularly Confirmed Pseudomyogenic Hemangioendothelioma with Unusual EGFL7::FOSB Fusion in the Head and Neck Region of an Older Patient.
Ren D; Lou J; Wei K; Ifegwu I
Diagnostics (Basel); 2024 Feb; 14(3):. PubMed ID: 38337858
[TBL] [Abstract][Full Text] [Related]
19. Primary pseudomyogenic haemangioendothelioma of bone: report of two cases.
Righi A; Gambarotti M; Picci P; Dei Tos AP; Vanel D
Skeletal Radiol; 2015 May; 44(5):727-31. PubMed ID: 25300339
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas.
Brunhara BB; Becker AP; Neder L; Gonçalves PG; de Oliveira C; Clara CA; Reis RM; Bidinotto LT
Neuropathology; 2021 Feb; 41(1):21-28. PubMed ID: 33191640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
